SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?


To: Jibacoa who wrote (1816)7/6/2007 2:28:25 PM
From: Jibacoa  Read Replies (2) | Respond to of 3722
 
LGND Seems to have found support at the $6.40 level. It needs to close above its Jun21 H of 7.37 before it can start closing some of its Apr21 DG.

bigcharts.marketwatch.com

There have been some recent insider's buys.<g>

finance.yahoo.com

Bernard



To: Jibacoa who wrote (1816)10/4/2007 11:01:30 AM
From: Jibacoa  Read Replies (1) | Respond to of 3722
 
CVTX Has been forming a base at the $9.10 level.<g>

bigcharts.marketwatch.com

It has applied to the FDA for a revision on the label for its Ranexa for the treatment of angina as it believes that data from the MERLIN TIMI-36 study could support expansion of the existing Ranexa indication to first line angina. (Ranexa is currently approved for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and should be used in combination with amlodipine, beta-blockers or nitrates.)

The problem CVTX has with Ranexa is that some insurance companies have been reluctant to cover the drug or have it as a non-preferred treatment. But if the FDA does approve the change in labeling, (the decision is expected next year)the sales of Ranexa should benefit as there are about 9M patients treated for angina mainly with generic drugs.

With the FDA approval, it seems there is a chance for CVTX to have a 50% gain from present levels.<g>

bigcharts.marketwatch.com

Bernard